Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838591 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma
A Phase 2 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00838591 is a Phase 2 study that has completed, run by MediciNova. The registered enrollment target is 176 participants.
The verdict
NCT00838591, a Phase 2 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.
Interventions
- DRUG Placebo
- DRUG MN-221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838591
The ClinicalTrials.gov registry entry for NCT00838591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00838591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838591 about?
NCT00838591 is a clinical study titled "Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma". The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.
What is the current status of trial NCT00838591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2009-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00838591?
The interventions under investigation include: Placebo (DRUG), MN-221 (DRUG).
Who is sponsoring clinical trial NCT00838591?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.